Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial

A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery

(2021) P. Pautier et al.   ESMO Open

Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

(2020) Lorenzo D’Ambrosio et al.   CANCER

Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas

(2020) William D. Tap et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial

(2019) Gianni Bisogno et al.   LANCET ONCOLOGY

Options for treating different soft tissue sarcoma subtypes

(2018) Isabelle Ray-Coquard et al.   Future Oncology

Soft Tissue and Uterine Leiomyosarcoma

(2018) Suzanne George et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial

(2017) Beatrice Seddon et al.   LANCET ONCOLOGY

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

(2017) William D Tap et al.   LANCET ONCOLOGY

Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study

(2016) Javier Martin-Broto et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

(2016) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

(2016) Patrick Schöffski et al.   LANCET

Randomized Phase III Trial of Gemcitabine Plus Docetaxel Plus Bevacizumab or Placebo As First-Line Treatment for Metastatic Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study

(2015) Martee L. Hensley et al.   JOURNAL OF CLINICAL ONCOLOGY

Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial

(2015) Axel Le Cesne et al.   LANCET ONCOLOGY

Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial

(2015) Patricia Pautier et al.   LANCET ONCOLOGY

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

(2014) Ian Judson et al.   LANCET ONCOLOGY

Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study

(2013) B. L. Samuels et al.   ANNALS OF ONCOLOGY

A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study

(2011) Bradley J. Monk et al.   GYNECOLOGIC ONCOLOGY

Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing

(2011) Françoise Ducimetière et al.   PLoS One

Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy

(2009) N. Penel et al.   ANNALS OF ONCOLOGY

Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma

(2008) J.-Y. Blay et al.   CLINICAL CANCER RESEARCH

Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer

(2008) C. Sessa et al.   EUROPEAN JOURNAL OF CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

(2008) Nicolas Penel et al.   JOURNAL OF CLINICAL ONCOLOGY